Abstract
Purpose: Hypertrophic changes in chondrocytes have a potential role in early and late osteoarthritis (OA) progression. RUNX2 is a master regulator of chondrocyte hypertrophy and the RUNX2-activated catabolic factors such as MMP13 and ADAMTS5 are involved in cartilage degradation, so RUNX2 could also be used as a target to alleviate inflammation associated with OA. Thus, inhibition of RUNX2-mediated changes such as chondrocyte hypertrophy in OA joint tissue may be one of the therapeutic targets to slow down the further OA progression.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
